5 Mar 2021 16:54
Â
Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
Â
PDMR Transaction Notification
Â
London, UK, 05 March 2021: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that Hans Peter Hasler, Non-Executive Chairman, acquired 200,000 Ordinary Shares in the Company on 05 March 2021 at an average price of 0.375 pence per share. Following the transaction, Mr Hasler has a beneficial interest in 500,000 shares.
Â
The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Â
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
Â
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a. | Name | Hans Peter Hasler | ||||
2. | Reason for the notification | |||||
a. | Position/status | Non-Executive Chairman | ||||
b. | Initial notification /Amendment | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a. | Name | Shield Therapeutics plc | ||||
b. | LEI | 213800G74QWY15FC3W71 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5p each in the capital of the Company    ISIN of Ordinary Shares: GB00BYV81293 | ||||
b. | Nature of the transaction |  Acquisition of Ordinary Shares  | ||||
c. | Price(s) and volume(s) | Â
| ||||
d. | Aggregated information · Aggregated volume · Price  |  200,000  £75,000  | ||||
e. | Date of the transaction | 2021-03-05 | ||||
f. | Place of the transaction | London Stock Exchange, AIM Market  |
Â
Â
Â
Â
Â
Â
For further information, please contact:
Â
Shield Therapeutics plc | +44 (0) 191 511 8500 | ||
Tim Watts (CEO) | |||
Peel Hunt LLP - Nominated Adviser, Joint Broker and Bookrunner | +44 (0) 20 7148 8900 | ||
James Steel / Dr Christopher Golden | |||
finnCap Ltd - Joint Broker and Bookrunner | +44 (0) 20 7220 0500 | ||
Geoff Nash / Matthew Radley / Alice Lane | |||
Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
Paul McManus / Lianne Cawthorne | or shield@walbrookpr.com | ||
Â
Â
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol)®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com
Â